Clinical Trial Detail

NCT ID NCT01321437
Title Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of California, Irvine
Indications

melanoma

Therapies

Axitinib

Age Groups: senior adult

No variant requirements are available.